-
1
-
-
0037158606
-
Thrombotic microangiopathies
-
Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600
-
(2002)
N Engl J Med
, vol.347
, pp. 589-600
-
-
Moake, J.L.1
-
2
-
-
77955883153
-
Complement: A key system for immune surveillance and homeostasis
-
Ricklin D et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-797
-
(2010)
Nat Immunol
, vol.11
, pp. 785-797
-
-
Ricklin, D.1
-
5
-
-
84948716605
-
Complement, a target for therapy in inflammatory and degenerative diseases
-
Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-877
-
(2015)
Nat Rev Drug Discov
, vol.14
, pp. 857-877
-
-
Morgan, B.P.1
Harris, C.L.2
-
6
-
-
0030441149
-
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
-
Thomas TC et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33:1389-1401
-
(1996)
Mol Immunol
, vol.33
, pp. 1389-1401
-
-
Thomas, T.C.1
-
7
-
-
0036667136
-
Eculizumab (Alexion)
-
Kaplan M. Eculizumab (Alexion). Curr Opin Invest Drugs 2002;3:1017-1023
-
(2002)
Curr Opin Invest Drugs
, vol.3
, pp. 1017-1023
-
-
Kaplan, M.1
-
8
-
-
10744228553
-
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
-
Hillmen P et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-559
-
(2004)
N Engl J Med
, vol.350
, pp. 552-559
-
-
Hillmen, P.1
-
9
-
-
84991765484
-
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future
-
Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-240
-
(2016)
Semin Immunol
, vol.28
, pp. 223-240
-
-
Risitano, A.M.1
Marotta, S.2
-
10
-
-
84921387621
-
Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
-
Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-320
-
(2015)
Transl Res
, vol.165
, pp. 306-320
-
-
Wong, E.K.1
Kavanagh, D.2
-
11
-
-
59449088846
-
Eculizumab for congenital atypical hemolytic-uremic syndrome
-
Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:544-546
-
(2009)
N Engl J Med
, vol.360
, pp. 544-546
-
-
Gruppo, R.A.1
Rother, R.P.2
-
12
-
-
59449107473
-
Eculizumab for atypical hemolyticuremic syndrome
-
Nurnberger J et al. Eculizumab for atypical hemolyticuremic syndrome. N Engl JMed 2009;360:542-544
-
(2009)
N Engl JMed
, vol.360
, pp. 542-544
-
-
Nurnberger, J.1
-
13
-
-
84878589219
-
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome
-
Legendre CM et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-2181
-
(2013)
N Engl J Med
, vol.368
, pp. 2169-2181
-
-
Legendre, C.M.1
-
14
-
-
84973365170
-
Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis
-
Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319-329
-
(2016)
Curr Opin Infect Dis
, vol.29
, pp. 319-329
-
-
Benamu, E.1
Montoya, J.G.2
-
15
-
-
85017234165
-
Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
-
Goodship TH et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016
-
(2016)
Kidney Int
-
-
Goodship, T.H.1
-
16
-
-
84930607950
-
Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome
-
Cullinan N et al. Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome. Pediatrics 2015;135:e1506-e1509
-
(2015)
Pediatrics
, vol.135
, pp. e1506-e1509
-
-
Cullinan, N.1
-
17
-
-
84874435634
-
Meningococcal sepsis complicating eculizumab treatment despite prior vaccination
-
Struijk GH et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013;13:819-820
-
(2013)
Am J Transplant
, vol.13
, pp. 819-820
-
-
Struijk, G.H.1
-
18
-
-
84956764057
-
Eculizumab-related progressive multifocal leukoencephalopathy
-
Gomez-Cibeira E et al. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 2016;86:399-400
-
(2016)
Neurology
, vol.86
, pp. 399-400
-
-
Gomez-Cibeira, E.1
-
19
-
-
84939974908
-
Eculizumab hepatotoxicity in pediatric aHUS
-
Hayes W et al. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 2015;30:775-781
-
(2015)
Pediatr Nephrol
, vol.30
, pp. 775-781
-
-
Hayes, W.1
-
20
-
-
84863512960
-
Pathology after eculizumab in dense deposit disease and C3 GN
-
Herlitz LC et al. Pathology after eculizumab in dense deposit disease and C3 GN. J AmSoc Nephrol 2012;23:1229-1237
-
(2012)
J AmSoc Nephrol
, vol.23
, pp. 1229-1237
-
-
Herlitz, L.C.1
-
21
-
-
85037985917
-
Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: Genetic analysis prior to transplantation is essential
-
Dowen F, Wood K, Brown AL et al. Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. Clin Kidney J 2017
-
(2017)
Clin Kidney J
-
-
Dowen, F.1
Wood, K.2
Brown, A.L.3
-
22
-
-
84906077328
-
Syndromes of thrombotic microangiopathy
-
George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654-666
-
(2014)
N Engl J Med
, vol.371
, pp. 654-666
-
-
George, J.N.1
Nester, C.M.2
-
23
-
-
84936985706
-
Atypical aHUS: State of the art
-
Nester CM et al. Atypical aHUS: State of the art. Mol Immunol 2015;67:31-42
-
(2015)
Mol Immunol
, vol.67
, pp. 31-42
-
-
Nester, C.M.1
-
24
-
-
84965057545
-
The alternative pathway of complement and the thrombotic microangiopathies
-
Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci 2016;54:220-231
-
(2016)
Transfus Apher Sci
, vol.54
, pp. 220-231
-
-
Teoh, C.W.1
Riedl, M.2
Licht, C.3
-
25
-
-
0031970553
-
Genetic studies into inherited and sporadic hemolytic uremic syndrome
-
Warwicker P et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836-844
-
(1998)
Kidney Int
, vol.53
, pp. 836-844
-
-
Warwicker, P.1
-
26
-
-
84876044818
-
Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults
-
Fremeaux-Bacchi V et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8:554-562
-
(2013)
Clin J Am Soc Nephrol
, vol.8
, pp. 554-562
-
-
Fremeaux-Bacchi, V.1
-
27
-
-
77958587405
-
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype
-
Noris M et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-1859
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 1844-1859
-
-
Noris, M.1
-
28
-
-
34548309310
-
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome
-
Kavanagh D et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95-105
-
(2008)
Mol Immunol
, vol.45
, pp. 95-105
-
-
Kavanagh, D.1
-
29
-
-
67449119124
-
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome
-
Ferreira VP et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009;182:7009-7018
-
(2009)
J Immunol
, vol.182
, pp. 7009-7018
-
-
Ferreira, V.P.1
-
30
-
-
33747159590
-
Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
-
Caprioli J et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267-1279
-
(2006)
Blood
, vol.108
, pp. 1267-1279
-
-
Caprioli, J.1
-
31
-
-
20544437666
-
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome
-
Dragon-Durey MA et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-563
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 555-563
-
-
Dragon-Durey, M.A.1
-
32
-
-
75649133611
-
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome
-
Moore I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010;115:379-387
-
(2010)
Blood
, vol.115
, pp. 379-387
-
-
Moore, I.1
-
33
-
-
84858029055
-
Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: Disease-associated or an epiphenomenon?
-
Kavanagh D et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? ClinJ AmSoc Nephrol 2012;7:417-426
-
(2012)
ClinJ AmSoc Nephrol
, vol.7
, pp. 417-426
-
-
Kavanagh, D.1
-
34
-
-
84929629467
-
Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: One target, two diseases
-
Blanc C et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 2015;194:5129-5138
-
(2015)
J Immunol
, vol.194
, pp. 5129-5138
-
-
Blanc, C.1
-
35
-
-
84899769165
-
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
-
Sinha A et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014;85:1151-1160
-
(2014)
Kidney Int
, vol.85
, pp. 1151-1160
-
-
Sinha, A.1
-
36
-
-
84866556872
-
Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome
-
Blanc C et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012;189:3528-3537
-
(2012)
J Immunol
, vol.189
, pp. 3528-3537
-
-
Blanc, C.1
-
37
-
-
84929128976
-
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
-
Licht C et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061-1073
-
(2015)
Kidney Int
, vol.87
, pp. 1061-1073
-
-
Licht, C.1
-
38
-
-
84975266700
-
Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, open-label trial
-
Fakhouri F et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 2016;68:84-93
-
(2016)
Am J Kidney Dis
, vol.68
, pp. 84-93
-
-
Fakhouri, F.1
-
39
-
-
84964561130
-
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
-
Greenbaum LA et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-711
-
(2016)
Kidney Int
, vol.89
, pp. 701-711
-
-
Greenbaum, L.A.1
-
40
-
-
85025842535
-
Factor H autoantibody associated atypical haemolytic uraemic syndrome in children in the United Kingdom and Ireland (2000-2015)
-
Brocklebank V, Johnson S, Sheerin TP et al. Factor H autoantibody associated atypical haemolytic uraemic syndrome in children in the United Kingdom and Ireland (2000-2015). Kidney Int 2017
-
(2017)
Kidney Int
-
-
Brocklebank, V.1
Johnson, S.2
Sheerin, T.P.3
-
41
-
-
84876741397
-
Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: A tertiary case series
-
Forbes TA et al. Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series. Pediatr Transplant 2013;17:E93-E99
-
(2013)
Pediatr Transplant
, vol.17
, pp. E93-E99
-
-
Forbes, T.A.1
-
42
-
-
84964480157
-
A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience
-
Sheerin NS et al. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016;109:27-33
-
(2016)
QJM
, vol.109
, pp. 27-33
-
-
Sheerin, N.S.1
-
43
-
-
84870534251
-
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation
-
Zuber J et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012;12:3337-3354
-
(2012)
Am J Transplant
, vol.12
, pp. 3337-3354
-
-
Zuber, J.1
-
44
-
-
84917673672
-
Atypical hemolytic uremic syndrome recurrence after kidney transplantation
-
Matar D et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014;98:1205-1212
-
(2014)
Transplantation
, vol.98
, pp. 1205-1212
-
-
Matar, D.1
-
45
-
-
79958202220
-
Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome
-
Nester C et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011;6:1488-1494
-
(2011)
Clin J Am Soc Nephrol
, vol.6
, pp. 1488-1494
-
-
Nester, C.1
-
46
-
-
77951876953
-
Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome
-
Zimmerhackl LB et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl JMed 2010;362:1746-1748
-
(2010)
N Engl JMed
, vol.362
, pp. 1746-1748
-
-
Zimmerhackl, L.B.1
-
47
-
-
84863208524
-
Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein
-
Krid S et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012;12:1938-1944
-
(2012)
Am J Transplant
, vol.12
, pp. 1938-1944
-
-
Krid, S.1
-
48
-
-
80052473232
-
Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome
-
Weitz M et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:1325-1329
-
(2011)
Pediatr Nephrol
, vol.26
, pp. 1325-1329
-
-
Weitz, M.1
-
49
-
-
84890562904
-
Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene
-
Roman-Ortiz E et al. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol 2014;29:149-153
-
(2014)
Pediatr Nephrol
, vol.29
, pp. 149-153
-
-
Roman-Ortiz, E.1
-
50
-
-
84883374274
-
Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation
-
Pelicano MB et al. Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation. Transplantation 2013;96:e26-e29
-
(2013)
Transplantation
, vol.96
, pp. e26-e29
-
-
Pelicano, M.B.1
-
51
-
-
84906097193
-
Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation
-
Ranch D et al. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation. Pediatr Transplant 2014;18:E185-E189
-
(2014)
Pediatr Transplant
, vol.18
, pp. E185-E189
-
-
Ranch, D.1
-
52
-
-
84870161966
-
Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: A case report
-
Xie L et al. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc 2012;44:3037-3040
-
(2012)
Transplant Proc
, vol.44
, pp. 3037-3040
-
-
Xie, L.1
-
53
-
-
84942924628
-
Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: The experience of the Australian compassionate access cohort
-
Mallett A et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J 2015;45:1054-1065
-
(2015)
Intern Med J
, vol.45
, pp. 1054-1065
-
-
Mallett, A.1
-
54
-
-
84995799460
-
Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab
-
Riddell A, Goodship T, Bingham C. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab. Clin Nephrol 2016;86:200-202
-
(2016)
Clin Nephrol
, vol.86
, pp. 200-202
-
-
Riddell, A.1
Goodship, T.2
Bingham, C.3
-
55
-
-
84894107600
-
Liver-kidney transplantation to cure atypical HUS: Still an option post-eculizumab?
-
Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol 2014;29:329-332
-
(2014)
Pediatr Nephrol
, vol.29
, pp. 329-332
-
-
Saland, J.1
-
56
-
-
33644914494
-
Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome
-
Oyen O et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006;6:412-418
-
(2006)
Am J Transplant
, vol.6
, pp. 412-418
-
-
Oyen, O.1
-
57
-
-
70350130833
-
Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome
-
Chatelet V et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009;9:2644-2645
-
(2009)
Am J Transplant
, vol.9
, pp. 2644-2645
-
-
Chatelet, V.1
-
58
-
-
84863724130
-
Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft
-
Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int 2012;25:e93-e95
-
(2012)
Transpl Int
, vol.25
, pp. e93-e95
-
-
Alachkar, N.1
Bagnasco, S.M.2
Montgomery, R.A.3
-
59
-
-
84868003869
-
Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
-
Duran CE et al. Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome. Clin Kidney J 2012;5:28-30
-
(2012)
Clin Kidney J
, vol.5
, pp. 28-30
-
-
Duran, C.E.1
-
60
-
-
84940991737
-
Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: Case report demonstrating successful treatment with eculizumab
-
Iqbal Z et al. Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: case report demonstrating successful treatment with eculizumab. Transplant Proc 2015;47:2258-2261
-
(2015)
Transplant Proc
, vol.47
, pp. 2258-2261
-
-
Iqbal, Z.1
-
61
-
-
77950955452
-
Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation
-
Larrea CF et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010;89:903-904
-
(2010)
Transplantation
, vol.89
, pp. 903-904
-
-
Larrea, C.F.1
-
62
-
-
77949570344
-
Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation
-
Davin JC et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010;55:708-711
-
(2010)
Am J Kidney Dis
, vol.55
, pp. 708-711
-
-
Davin, J.C.1
-
63
-
-
84874417661
-
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome
-
Le Quintrec M et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013;13:663-675
-
(2013)
Am J Transplant
, vol.13
, pp. 663-675
-
-
Le Quintrec, M.1
-
64
-
-
34548400755
-
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background
-
Bresin E et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88-99
-
(2006)
Clin J Am Soc Nephrol
, vol.1
, pp. 88-99
-
-
Bresin, E.1
-
65
-
-
84887024143
-
Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation
-
Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013;22:704-712
-
(2013)
Curr Opin Nephrol Hypertens
, vol.22
, pp. 704-712
-
-
Noris, M.1
Remuzzi, G.2
-
66
-
-
48349086641
-
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation
-
Le Quintrec M et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008;8:1694-1701
-
(2008)
Am J Transplant
, vol.8
, pp. 1694-1701
-
-
Le Quintrec, M.1
-
67
-
-
84902139084
-
Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report
-
Safa K et al. Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report. Clin Nephrol 2015;83:125-129
-
(2015)
Clin Nephrol
, vol.83
, pp. 125-129
-
-
Safa, K.1
-
68
-
-
84976534215
-
Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab
-
Ikeda T et al. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab. Nephrology (Carlton) 2016;21:35-40
-
(2016)
Nephrology (Carlton)
, vol.21
, pp. 35-40
-
-
Ikeda, T.1
-
69
-
-
84979067029
-
Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab
-
Juega-Marino FJ et al. Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab. Nefrologia 2016;36:328-329
-
(2016)
Nefrologia
, vol.36
, pp. 328-329
-
-
Juega-Marino, F.J.1
-
70
-
-
80054767700
-
Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab
-
Wilson CH et al. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011;92:e42-e43
-
(2011)
Transplantation
, vol.92
, pp. e42-e43
-
-
Wilson, C.H.1
-
71
-
-
79959390955
-
Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreaskidney transplantation-a case report
-
Chandran S et al. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreaskidney transplantation-a case report. Transplant Proc 2011;43:2097-2101
-
(2011)
Transplant Proc
, vol.43
, pp. 2097-2101
-
-
Chandran, S.1
-
72
-
-
0141781175
-
Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation
-
Karthikeyan V et al. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 2003;3:1289-1294
-
(2003)
Am J Transplant
, vol.3
, pp. 1289-1294
-
-
Karthikeyan, V.1
-
73
-
-
85030392725
-
Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy
-
Cicora F et al. Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy. Case Rep Med 2013;2013:260254
-
(2013)
Case Rep Med
, vol.2013
, pp. 260254
-
-
Cicora, F.1
-
74
-
-
84923673542
-
De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus
-
Cortina G et al. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus. Pediatr Nephrol 2015;30:693-697
-
(2015)
Pediatr Nephrol
, vol.30
, pp. 693-697
-
-
Cortina, G.1
-
75
-
-
41049113480
-
Thrombotic microangiopathy following pancreas after kidney transplants
-
Lipshutz GS et al. Thrombotic microangiopathy following pancreas after kidney transplants. Clin Transplant 2008;22:236-241
-
(2008)
Clin Transplant
, vol.22
, pp. 236-241
-
-
Lipshutz, G.S.1
-
76
-
-
84867983968
-
The role of complement in antibody-mediated rejection in kidney transplantation
-
Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012;8:670-678
-
(2012)
Nat Rev Nephrol
, vol.8
, pp. 670-678
-
-
Stegall, M.D.1
Chedid, M.F.2
Cornell, L.D.3
-
77
-
-
84865611225
-
Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab
-
Noone D et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012;12:2546-2553
-
(2012)
Am J Transplant
, vol.12
, pp. 2546-2553
-
-
Noone, D.1
-
78
-
-
85016793639
-
Eculizumab for the treatment of severe antibody-mediated rejection: A case report and review of the literature
-
Tran D et al. Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature. Case Rep Transplant 2016;2016:9874261
-
(2016)
Case Rep Transplant
, vol.2016
, pp. 9874261
-
-
Tran, D.1
-
79
-
-
84869038452
-
Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: Case reports
-
Gonzalez-Roncero F et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012;44:2690-2694
-
(2012)
Transplant Proc
, vol.44
, pp. 2690-2694
-
-
Gonzalez-Roncero, F.1
-
80
-
-
84870244762
-
Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant
-
Stewart ZA et al. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012;44:3033-3036
-
(2012)
Transplant Proc
, vol.44
, pp. 3033-3036
-
-
Stewart, Z.A.1
-
81
-
-
84555210096
-
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients
-
Stegall MD et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405-2413
-
(2011)
Am J Transplant
, vol.11
, pp. 2405-2413
-
-
Stegall, M.D.1
-
82
-
-
84928089457
-
Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year
-
Cornell LD et al. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 2015;15:1293-1302
-
(2015)
Am J Transplant
, vol.15
, pp. 1293-1302
-
-
Cornell, L.D.1
-
83
-
-
85014072324
-
Eculizumab therapy for chronic antibodymediated injury in kidney transplant recipients: A pilot randomized controlled trial
-
Kulkarni S et al. Eculizumab therapy for chronic antibodymediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am J Transplant 2016
-
(2016)
Am J Transplant
-
-
Kulkarni, S.1
-
84
-
-
84891825219
-
Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody
-
Ghirardo G et al. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant 2014;18:E1-E5
-
(2014)
Pediatr Transplant
, vol.18
, pp. E1-E5
-
-
Ghirardo, G.1
-
85
-
-
58049206825
-
The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection
-
Locke JE et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009;9:231-235
-
(2009)
Am J Transplant
, vol.9
, pp. 231-235
-
-
Locke, J.E.1
-
86
-
-
84922658935
-
Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient
-
Chehade H et al. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics 2015;135:e551-e555
-
(2015)
Pediatrics
, vol.135
, pp. e551-e555
-
-
Chehade, H.1
-
87
-
-
79960120521
-
Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation
-
Biglarnia AR et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011;24:e61-e66
-
(2011)
Transpl Int
, vol.24
, pp. e61-e66
-
-
Biglarnia, A.R.1
-
88
-
-
84927798214
-
Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts
-
Burbach M et al. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 2014;98:1056-1059
-
(2014)
Transplantation
, vol.98
, pp. 1056-1059
-
-
Burbach, M.1
-
89
-
-
84922014185
-
Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation
-
Orandi BJ et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014;98:857-863
-
(2014)
Transplantation
, vol.98
, pp. 857-863
-
-
Orandi, B.J.1
-
90
-
-
84911129829
-
Antibody-mediated rejection despite inhibition of terminal complement
-
Bentall A et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014;27:1235-1243
-
(2014)
Transpl Int
, vol.27
, pp. 1235-1243
-
-
Bentall, A.1
-
91
-
-
84939456967
-
Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: A single-center experience
-
Yelken B et al. Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience. Transplant Proc 2015;47:1754-1759
-
(2015)
Transplant Proc
, vol.47
, pp. 1754-1759
-
-
Yelken, B.1
-
92
-
-
74949094555
-
KDIGO clinical practice guideline for the care of kidney transplant recipients
-
Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9:S1-S155
-
(2009)
Am J Transplant
, vol.9
, pp. S1-S155
-
-
-
93
-
-
84922349792
-
Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation
-
Bruneau S et al. Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. Blood 2015;125:1038-1046
-
(2015)
Blood
, vol.125
, pp. 1038-1046
-
-
Bruneau, S.1
-
94
-
-
84878608990
-
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
-
Lemaire M et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013;45:531-536
-
(2013)
Nat Genet
, vol.45
, pp. 531-536
-
-
Lemaire, M.1
-
95
-
-
84908170447
-
Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome
-
Sanchez Chinchilla D et al. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1611-1619
-
(2014)
Clin J Am Soc Nephrol
, vol.9
, pp. 1611-1619
-
-
Sanchez Chinchilla, D.1
-
96
-
-
84930441272
-
Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome
-
Mele C et al. Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2015;10:1011-1019
-
(2015)
Clin J Am Soc Nephrol
, vol.10
, pp. 1011-1019
-
-
Mele, C.1
-
97
-
-
84902135216
-
Phenotypic expansion of DGKE-associated diseases
-
Westland R et al. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014;25:1408-1414
-
(2014)
J Am Soc Nephrol
, vol.25
, pp. 1408-1414
-
-
Westland, R.1
-
98
-
-
84883420511
-
Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy
-
Tati R et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013;191:2184-2193
-
(2013)
J Immunol
, vol.191
, pp. 2184-2193
-
-
Tati, R.1
-
99
-
-
20144365269
-
Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies
-
Ruiz-Torres MP et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005;93:443-452
-
(2005)
Thromb Haemost
, vol.93
, pp. 443-452
-
-
Ruiz-Torres, M.P.1
-
100
-
-
84994607433
-
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura
-
Cao W et al. Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura. Haematologica 2016;101:1319-1326
-
(2016)
Haematologica
, vol.101
, pp. 1319-1326
-
-
Cao, W.1
-
101
-
-
84860474599
-
Complement activation in thrombotic thrombocytopenic purpura
-
Reti M et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012;10:791-798
-
(2012)
J Thromb Haemost
, vol.10
, pp. 791-798
-
-
Reti, M.1
-
102
-
-
84894705729
-
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
-
Westwood JP et al. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol 2014;164:858-866
-
(2014)
Br J Haematol
, vol.164
, pp. 858-866
-
-
Westwood, J.P.1
-
103
-
-
84885339216
-
Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura
-
Wu TC et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 2013;11:1925-1927
-
(2013)
J Thromb Haemost
, vol.11
, pp. 1925-1927
-
-
Wu, T.C.1
-
104
-
-
84959575823
-
Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency
-
Fan X et al. Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. Int J Hematol 2016;103:283-291
-
(2016)
Int J Hematol
, vol.103
, pp. 283-291
-
-
Fan, X.1
-
105
-
-
23944468642
-
Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement
-
Noris M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005;16:1177-1183
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 1177-1183
-
-
Noris, M.1
-
106
-
-
84861526957
-
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura
-
Chapin J et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012;157:772-774
-
(2012)
Br J Haematol
, vol.157
, pp. 772-774
-
-
Chapin, J.1
-
107
-
-
84880700770
-
Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: Additional data and clinical follow-up
-
Tsai E et al. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 2013;162:558-559
-
(2013)
Br J Haematol
, vol.162
, pp. 558-559
-
-
Tsai, E.1
-
108
-
-
84948085489
-
Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab
-
Pecoraro C et al. Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab. Am J Kidney Dis 2015;66:1067-1070
-
(2015)
Am J Kidney Dis
, vol.66
, pp. 1067-1070
-
-
Pecoraro, C.1
-
109
-
-
84975795988
-
Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The seventh special issue
-
Schwartz J et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149-162
-
(2016)
J Clin Apher
, vol.31
, pp. 149-162
-
-
Schwartz, J.1
-
110
-
-
80051866867
-
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
-
Scully M et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011;118:1746-1753
-
(2011)
Blood
, vol.118
, pp. 1746-1753
-
-
Scully, M.1
-
111
-
-
84934434760
-
A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab
-
Clark WF et al. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. Br J Haematol 2015;170:208-217
-
(2015)
Br J Haematol
, vol.170
, pp. 208-217
-
-
Clark, W.F.1
-
112
-
-
84995581864
-
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study
-
Benhamou Y et al. Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study. Am J Hematol 2016
-
(2016)
Am J Hematol
-
-
Benhamou, Y.1
-
113
-
-
84959293895
-
Caplacizumab for acquired thrombotic thrombocytopenic purpura
-
Peyvandi F et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016;374:511-522
-
(2016)
N Engl J Med
, vol.374
, pp. 511-522
-
-
Peyvandi, F.1
-
114
-
-
77952556624
-
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations
-
Fakhouri F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859-67
-
(2010)
J Am Soc Nephrol
, vol.21
, pp. 859-867
-
-
Fakhouri, F.1
-
115
-
-
84880958391
-
Eculizumab for atypical hemolytic uremic syndrome in pregnancy
-
Ardissino G et al. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 2013;122(2 Pt 2):487-489
-
(2013)
Obstet Gynecol
, vol.122
, Issue.2
, pp. 487-489
-
-
Ardissino, G.1
-
116
-
-
84879576278
-
Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab
-
Zschiedrich S, Prager EP, Kuehn EW. Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann Intern Med 2013;159:176
-
(2013)
Ann Intern Med
, vol.159
, pp. 176
-
-
Zschiedrich, S.1
Prager, E.P.2
Kuehn, E.W.3
-
117
-
-
84904095940
-
Thrombotic thrombocytopenic purpura and pregnancy: Presentation, management, and subsequent pregnancy outcomes
-
Scully M et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014;124:211-219
-
(2014)
Blood
, vol.124
, pp. 211-219
-
-
Scully, M.1
-
118
-
-
84963600144
-
Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome
-
Vaught AJ et al. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp Hematol 2016;44:390-398
-
(2016)
Exp Hematol
, vol.44
, pp. 390-398
-
-
Vaught, A.J.1
-
119
-
-
0025113399
-
Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count
-
Haeger M, Unander M, Bengtsson A. Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1990;76:698-702
-
(1990)
Obstet Gynecol
, vol.76
, pp. 698-702
-
-
Haeger, M.1
Unander, M.2
Bengtsson, A.3
-
120
-
-
77950628595
-
Activation of the complement system in normal pregnancy and preeclampsia
-
Derzsy Z et al. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010;47:1500-1506
-
(2010)
Mol Immunol
, vol.47
, pp. 1500-1506
-
-
Derzsy, Z.1
-
121
-
-
84982141403
-
Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia
-
He Y et al. Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol 2016;76:205-211
-
(2016)
Am J Reprod Immunol
, vol.76
, pp. 205-211
-
-
He, Y.1
-
122
-
-
70349978795
-
Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count
-
Ari E et al. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Am J Reprod Immunol 2009;62:238-242
-
(2009)
Am J Reprod Immunol
, vol.62
, pp. 238-242
-
-
Ari, E.1
-
123
-
-
57649241639
-
Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome
-
Fakhouri F et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008;112:4542-4545
-
(2008)
Blood
, vol.112
, pp. 4542-4545
-
-
Fakhouri, F.1
-
124
-
-
84867566240
-
The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome
-
Crovetto F et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med 2012;25:2322-2325
-
(2012)
J Matern Fetal Neonatal Med
, vol.25
, pp. 2322-2325
-
-
Crovetto, F.1
-
125
-
-
79953691827
-
Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort
-
Salmon JE et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011;8:e1001013
-
(2011)
PLoS Med
, vol.8
, pp. e1001013
-
-
Salmon, J.E.1
-
126
-
-
84941276223
-
Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria
-
Kelly RJ et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015;373:1032-1039
-
(2015)
N Engl J Med
, vol.373
, pp. 1032-1039
-
-
Kelly, R.J.1
-
127
-
-
85026919072
-
Atypical haemolytic uraemic syndrome and pregnancy: Outcome with ongoing eculizumab
-
Servais A et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant 2016
-
(2016)
Nephrol Dial Transplant
-
-
Servais, A.1
-
128
-
-
84873288473
-
Eculizumab for the treatment of preeclampsia/HELLP syndrome
-
Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013;34:201-203
-
(2013)
Placenta
, vol.34
, pp. 201-203
-
-
Burwick, R.M.1
Feinberg, B.B.2
-
129
-
-
85030442306
-
Renal thrombotic microangiopathy in patients with cblC defect: Review of an under-recognized entity
-
Beck BB et al. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol 2016
-
(2016)
Pediatr Nephrol
-
-
Beck, B.B.1
-
130
-
-
78449267023
-
CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency
-
Bouts AH et al. CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 2010;25:2547-2548
-
(2010)
Pediatr Nephrol
, vol.25
, pp. 2547-2548
-
-
Bouts, A.H.1
-
131
-
-
14844321537
-
Late-onset thrombocytic microangiopathy caused by cblC disease: Association with a factor H mutation
-
Guigonis V et al. Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005;45:588-595
-
(2005)
Am J Kidney Dis
, vol.45
, pp. 588-595
-
-
Guigonis, V.1
-
132
-
-
84896514393
-
Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency
-
Cornec-Le Gall E et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014;63:119-123
-
(2014)
Am J Kidney Dis
, vol.63
, pp. 119-123
-
-
Cornec-Le Gall, E.1
-
133
-
-
79960435714
-
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis
-
Morigi M et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011;187:172-180
-
(2011)
J Immunol
, vol.187
, pp. 172-180
-
-
Morigi, M.1
-
134
-
-
85003678427
-
Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury
-
Ozaki M et al. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int 2016;90:774-782
-
(2016)
Kidney Int
, vol.90
, pp. 774-782
-
-
Ozaki, M.1
-
135
-
-
84912520417
-
Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement
-
Locatelli M et al. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol 2014;25:1786-1798
-
(2014)
J Am Soc Nephrol
, vol.25
, pp. 1786-1798
-
-
Locatelli, M.1
-
136
-
-
70350693665
-
Shiga toxin activates complement and binds factor H: Evidence for an active role of complement in hemolytic uremic syndrome
-
Orth D et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009;182:6394-6400
-
(2009)
J Immunol
, vol.182
, pp. 6394-6400
-
-
Orth, D.1
-
137
-
-
84889579190
-
Interaction of Shiga toxin 2 with complement regulators of the factor H protein family
-
Poolpol K et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 2014;58:77-84
-
(2014)
Mol Immunol
, vol.58
, pp. 77-84
-
-
Poolpol, K.1
-
138
-
-
79956293593
-
Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome
-
Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011;117:5503-5513
-
(2011)
Blood
, vol.117
, pp. 5503-5513
-
-
Stahl, A.L.1
Sartz, L.2
Karpman, D.3
-
139
-
-
84924358744
-
Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome
-
Arvidsson I et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. JImmunol 2015;194:2309-2318
-
(2015)
JImmunol
, vol.194
, pp. 2309-2318
-
-
Arvidsson, I.1
-
140
-
-
85007367202
-
Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome
-
Ahlenstiel-Grunow T et al. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 2016;31:1114-1121
-
(2016)
Nephrol Dial Transplant
, vol.31
, pp. 1114-1121
-
-
Ahlenstiel-Grunow, T.1
-
141
-
-
84930415185
-
Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome
-
Ferraris JR et al. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 2015;181:118-125
-
(2015)
Clin Exp Immunol
, vol.181
, pp. 118-125
-
-
Ferraris, J.R.1
-
142
-
-
73649122762
-
Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome
-
Thurman JM et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1920-1924
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, pp. 1920-1924
-
-
Thurman, J.M.1
-
143
-
-
84881374227
-
Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations
-
Alberti M et al. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant 2013;13:2201-2206
-
(2013)
Am J Transplant
, vol.13
, pp. 2201-2206
-
-
Alberti, M.1
-
144
-
-
84947485143
-
CFH gene mutation in a case of Shiga toxinassociated hemolytic uremic syndrome (STEC-HUS)
-
Caillaud C et al. CFH gene mutation in a case of Shiga toxinassociated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2016;31:157-161
-
(2016)
Pediatr Nephrol
, vol.31
, pp. 157-161
-
-
Caillaud, C.1
-
145
-
-
85013016536
-
A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome
-
Challis RC et al. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2016;27:1617-1624
-
(2016)
J Am Soc Nephrol
, vol.27
, pp. 1617-1624
-
-
Challis, R.C.1
-
146
-
-
85037989595
-
Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome
-
Westra D et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 2016
-
(2016)
Pediatr Nephrol
-
-
Westra, D.1
-
147
-
-
84868562798
-
Best supportive care and therapeutic plasma exchange with or without eculizumab in Shigatoxin-producing E. Coli O104:H4 induced haemolyticuraemic syndrome: An analysis of the German STEC-HUS registry
-
Kielstein JT et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shigatoxin-producing E. coli O104:H4 induced haemolyticuraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012;27:3807-3815
-
(2012)
Nephrol Dial Transplant
, vol.27
, pp. 3807-3815
-
-
Kielstein, J.T.1
-
148
-
-
84864876679
-
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: Case-control study
-
Menne J et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565
-
(2012)
BMJ
, vol.345
, pp. e4565
-
-
Menne, J.1
-
149
-
-
79959776422
-
Eculizumab in severe Shiga-toxinassociated HUS
-
Lapeyraque AL et al. Eculizumab in severe Shiga-toxinassociated HUS. NEngl J Med 2011;364:2561-2563
-
(2011)
NEngl J Med
, vol.364
, pp. 2561-2563
-
-
Lapeyraque, A.L.1
-
150
-
-
84885953550
-
Long-term outcomes of Shiga toxin hemolytic uremic syndrome
-
Spinale JM et al. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013;28:2097-2105
-
(2013)
Pediatr Nephrol
, vol.28
, pp. 2097-2105
-
-
Spinale, J.M.1
-
151
-
-
80053246996
-
Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: A prospective trial
-
Greinacher A et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378:1166-1173
-
(2011)
Lancet
, vol.378
, pp. 1166-1173
-
-
Greinacher, A.1
-
152
-
-
58249107186
-
Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: A systematic review of randomized controlled trials
-
Michael M et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;53:259-272
-
(2009)
Am J Kidney Dis
, vol.53
, pp. 259-272
-
-
Michael, M.1
-
153
-
-
84865491675
-
An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: Presentation and short-term outcome in children
-
Loos S et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012;55:753-759
-
(2012)
Clin Infect Dis
, vol.55
, pp. 753-759
-
-
Loos, S.1
-
154
-
-
27944505853
-
In vivo binding of complement regulator factor H by Streptococcus pneumoniae
-
Quin LR et al. In vivo binding of complement regulator factor H by Streptococcus pneumoniae. J Infect Dis 2005;192:1996-2003
-
(2005)
J Infect Dis
, vol.192
, pp. 1996-2003
-
-
Quin, L.R.1
-
155
-
-
84855256386
-
Is complement a culprit in infectioninduced forms of haemolytic uraemic syndrome?
-
Johnson S, Waters A. Is complement a culprit in infectioninduced forms of haemolytic uraemic syndrome? Immunobiology 2012;217:235-243
-
(2012)
Immunobiology
, vol.217
, pp. 235-243
-
-
Johnson, S.1
Waters, A.2
-
156
-
-
84881555729
-
Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?
-
Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses 2013;81:400-403
-
(2013)
Med Hypotheses
, vol.81
, pp. 400-403
-
-
Gilbert, R.D.1
Nagra, A.2
Haq, M.R.3
-
157
-
-
84884526601
-
The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome
-
Szilagyi A et al. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013;28:2237-2245
-
(2013)
Nephrol Dial Transplant
, vol.28
, pp. 2237-2245
-
-
Szilagyi, A.1
-
159
-
-
84992088843
-
Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
-
Jin A et al. Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab. Clin Kidney J 2016;9:576-579
-
(2016)
Clin Kidney J
, vol.9
, pp. 576-579
-
-
Jin, A.1
-
160
-
-
0037213442
-
Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy
-
Alpers CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney Int 2003;63:385-396
-
(2003)
Kidney Int
, vol.63
, pp. 385-396
-
-
Alpers, C.E.1
-
161
-
-
0033016111
-
Acute renal failure in the course of HIV infection: A single-institution retrospective study of ninetytwo patients and sixty renal biopsies
-
Peraldi MN et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninetytwo patients and sixty renal biopsies. Nephrol Dial Transplant 1999;14:1578-1585
-
(1999)
Nephrol Dial Transplant
, vol.14
, pp. 1578-1585
-
-
Peraldi, M.N.1
-
162
-
-
7444246754
-
HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: An observational study
-
Becker S et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004;39:S267-S275
-
(2004)
Clin Infect Dis
, vol.39
, pp. S267-S275
-
-
Becker, S.1
-
163
-
-
84938743746
-
Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: Case report and review of the literature
-
Java A et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int 2015;28:1121-1125
-
(2015)
Transpl Int
, vol.28
, pp. 1121-1125
-
-
Java, A.1
-
164
-
-
84856713252
-
Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: A novel role for bioactive lipids and soluble C5b-C9 as homing factors
-
Kim CH et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia 2012;26:106-116
-
(2012)
Leukemia
, vol.26
, pp. 106-116
-
-
Kim, C.H.1
-
165
-
-
84861820595
-
Antigen-presenting cell-derived complement modulates graft-versus-host disease
-
Kwan WH et al. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest 2012;122:2234-2238
-
(2012)
J Clin Invest
, vol.122
, pp. 2234-2238
-
-
Kwan, W.H.1
-
166
-
-
80052259769
-
Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
-
Mii A et al. Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Pathol Int 2011;61:518-527
-
(2011)
Pathol Int
, vol.61
, pp. 518-527
-
-
Mii, A.1
-
167
-
-
84929046376
-
Hematopoietic stem cell transplantationassociated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition
-
Sakamoto K et al. Hematopoietic stem cell transplantationassociated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition. Pediatr Transplant 2015;19:E97-E100
-
(2015)
Pediatr Transplant
, vol.19
, pp. E97-E100
-
-
Sakamoto, K.1
-
168
-
-
84904861838
-
Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: A study in children and young adults
-
Jodele S et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014;124:645-653
-
(2014)
Blood
, vol.124
, pp. 645-653
-
-
Jodele, S.1
-
169
-
-
27844507105
-
Hemolytic uremic syndrome after bone marrow transplantation: Clinical characteristics and outcome in children
-
Hale GA et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant 2005;11:912-920
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 912-920
-
-
Hale, G.A.1
-
170
-
-
84885717017
-
Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy
-
Jodele S et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013;122:2003-2007
-
(2013)
Blood
, vol.122
, pp. 2003-2007
-
-
Jodele, S.1
-
171
-
-
84960378679
-
The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy
-
Jodele S et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016;127:989-996
-
(2016)
Blood
, vol.127
, pp. 989-996
-
-
Jodele, S.1
-
172
-
-
84964855034
-
New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy
-
Jodele S et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci 2016;54:181-190
-
(2016)
Transfus Apher Sci
, vol.54
, pp. 181-190
-
-
Jodele, S.1
-
173
-
-
84946895923
-
Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: A study from the SFGM-TC
-
de Fontbrune FS et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 2015;99:1953-1959
-
(2015)
Transplantation
, vol.99
, pp. 1953-1959
-
-
De Fontbrune, F.S.1
-
174
-
-
84895786359
-
Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy
-
Jodele S et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014;20:518-525
-
(2014)
Biol Blood Marrow Transplant
, vol.20
, pp. 518-525
-
-
Jodele, S.1
-
175
-
-
84907206672
-
Hematopoietic transplant-associated thrombotic microangiopathy: Case report and review of diagnosis and treatments
-
Chapin J et al. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014;12:565-573
-
(2014)
Clin Adv Hematol Oncol
, vol.12
, pp. 565-573
-
-
Chapin, J.1
-
176
-
-
84875803456
-
Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy
-
Peffault de Latour R et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 2013;161:279-280
-
(2013)
Br J Haematol
, vol.161
, pp. 279-280
-
-
Peffault De Latour, R.1
-
177
-
-
84905676449
-
Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia
-
Okano M et al. Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia. Bone Marrow Transplant 2014;49:1116-1118
-
(2014)
Bone Marrow Transplant
, vol.49
, pp. 1116-1118
-
-
Okano, M.1
-
178
-
-
85014540072
-
Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation
-
Sevindik OG et al. Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation. Case Rep Hematol 2015;2015:425410
-
(2015)
Case Rep Hematol
, vol.2015
, pp. 425410
-
-
Sevindik, O.G.1
-
179
-
-
85132482865
-
Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease
-
Fernandez C et al. Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease. Hematol Rep 2015;7:6107
-
(2015)
Hematol Rep
, vol.7
, pp. 6107
-
-
Fernandez, C.1
-
180
-
-
84963621743
-
Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy
-
Vasu S et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 2016;51:1241-1244
-
(2016)
Bone Marrow Transplant
, vol.51
, pp. 1241-1244
-
-
Vasu, S.1
-
181
-
-
22344434696
-
Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation
-
Ho VT et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571-575
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 571-575
-
-
Ho, V.T.1
-
182
-
-
84951271153
-
Hematopoietic stem cell transplant-associated thrombotic microangiopathy
-
Elsallabi O et al. Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016;22:12-20
-
(2016)
Clin Appl Thromb Hemost
, vol.22
, pp. 12-20
-
-
Elsallabi, O.1
-
183
-
-
34447626285
-
ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: Close association with transplant-associated microangiopathy
-
Worel N et al. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci 2007;36:297-304
-
(2007)
Transfus Apher Sci
, vol.36
, pp. 297-304
-
-
Worel, N.1
-
184
-
-
34247895387
-
Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab
-
Au WY et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007;137:475-478
-
(2007)
Br J Haematol
, vol.137
, pp. 475-478
-
-
Au, W.Y.1
-
185
-
-
47849109877
-
Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura
-
Carella AM et al. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 2008;41:1063-1065
-
(2008)
Bone Marrow Transplant
, vol.41
, pp. 1063-1065
-
-
Carella, A.M.1
-
186
-
-
84901489226
-
Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling
-
Zhang C et al. Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling. Arterioscler Thromb Vasc Biol 2014;34:1240-1248
-
(2014)
Arterioscler Thromb Vasc Biol
, vol.34
, pp. 1240-1248
-
-
Zhang, C.1
-
187
-
-
84900873319
-
Antagonistof C5aR prevents cardiac remodeling in angiotensin II-induced hypertension
-
Zhang C et al. Antagonistof C5aR prevents cardiac remodeling in angiotensin II-induced hypertension. Am J Hypertens 2014;27:857-864
-
(2014)
Am J Hypertens
, vol.27
, pp. 857-864
-
-
Zhang, C.1
-
188
-
-
33947421167
-
Plasma levels of complement C3 is associated with development of hypertension: A longitudinal cohort study
-
Engstrom G et al. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens 2007;21:276-282
-
(2007)
J Hum Hypertens
, vol.21
, pp. 276-282
-
-
Engstrom, G.1
-
189
-
-
84864348884
-
Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population
-
Gan W et al. Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population. PLoS One 2012;7:e42010
-
(2012)
PLoS One
, vol.7
, pp. e42010
-
-
Gan, W.1
-
190
-
-
79952934453
-
Clinical features of malignant hypertension with thrombotic microangiopathy
-
Akimoto T et al. Clinical features of malignant hypertension with thrombotic microangiopathy. Clin Exp Hypertens 2011;33:77-83
-
(2011)
Clin Exp Hypertens
, vol.33
, pp. 77-83
-
-
Akimoto, T.1
-
191
-
-
84993736115
-
Differentiating malignant hypertensioninduced thrombotic microangiopathy from thrombotic thrombocytopenic purpura
-
Khanal N et al. Differentiating malignant hypertensioninduced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol 2015;6:97-102
-
(2015)
Ther Adv Hematol
, vol.6
, pp. 97-102
-
-
Khanal, N.1
-
192
-
-
84868350979
-
Malignant hypertension with reversible brainstem hypertensive encephalopathy and thrombotic microangiopathy
-
e17-e20
-
Deguchi I et al. Malignant hypertension with reversible brainstem hypertensive encephalopathy and thrombotic microangiopathy. J Stroke Cerebrovasc Dis 2012;21:915 e17-e20
-
(2012)
J Stroke Cerebrovasc Dis
, vol.21
, pp. 915
-
-
Deguchi, I.1
-
193
-
-
84880453521
-
Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies
-
Chapin J et al. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood 2013;121:4012-4013
-
(2013)
Blood
, vol.121
, pp. 4012-4013
-
-
Chapin, J.1
-
194
-
-
84963516592
-
Clopidogrel-induced thrombotic microangiopathy in a patient with hypocomplementemia
-
Tada K et al. Clopidogrel-induced thrombotic microangiopathy in a patient with hypocomplementemia. Intern Med 2016;55:969-973
-
(2016)
Intern Med
, vol.55
, pp. 969-973
-
-
Tada, K.1
-
195
-
-
84885045257
-
Eculizumab and drug-induced haemolyticuraemic syndrome
-
Faguer S et al. Eculizumab and drug-induced haemolyticuraemic syndrome. Clin Kidney J 2013;6:484-485
-
(2013)
Clin Kidney J
, vol.6
, pp. 484-485
-
-
Faguer, S.1
-
196
-
-
85020614909
-
Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy
-
Starck M, Wendtner CM. Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol 2013
-
(2013)
Br J Haematol
-
-
Starck, M.1
Wendtner, C.M.2
-
197
-
-
84989217805
-
Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: Case series and concise review
-
Al Ustwani O et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 2014;5:E30-E33
-
(2014)
J Gastrointest Oncol
, vol.5
, pp. E30-E33
-
-
Al Ustwani, O.1
-
198
-
-
85019827216
-
Gemcitabine-associated thrombotic microangiopathy: Response to complement inhibition and reinitiation of gemcitabine
-
Turner JL et al. Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine. Clin Colorectal Cancer 2016
-
(2016)
Clin Colorectal Cancer
-
-
Turner, J.L.1
-
199
-
-
84983060381
-
Proteasome inhibitor associated thrombotic microangiopathy
-
Yui JC et al. Proteasome inhibitor associated thrombotic microangiopathy. AmJ Hematol 2016;91:E348-E352
-
(2016)
AmJ Hematol
, vol.91
, pp. E348-E352
-
-
Yui, J.C.1
-
200
-
-
0034674030
-
Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura
-
Tsai HM et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794-799
-
(2000)
Ann Intern Med
, vol.132
, pp. 794-799
-
-
Tsai, H.M.1
-
201
-
-
70449560501
-
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
-
Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 2009;24:209-214
-
(2009)
J Clin Apher
, vol.24
, pp. 209-214
-
-
Gore, E.M.1
Jones, B.S.2
Marques, M.B.3
-
202
-
-
84962530615
-
Carfilzomib: A cause of drug associated thrombotic microangiopathy
-
Qaqish I et al. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci 2016;54:401-404
-
(2016)
Transfus Apher Sci
, vol.54
, pp. 401-404
-
-
Qaqish, I.1
-
203
-
-
33846445710
-
Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases
-
Francis KK et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist 2007;12:11-19
-
(2007)
Oncologist
, vol.12
, pp. 11-19
-
-
Francis, K.K.1
-
204
-
-
0024391413
-
Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry
-
Lesesne JB et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-789
-
(1989)
J Clin Oncol
, vol.7
, pp. 781-789
-
-
Lesesne, J.B.1
-
205
-
-
70249131553
-
Cancer awareness in atypical thrombotic microangiopathies
-
Oberic L et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist 2009;14:769-779
-
(2009)
Oncologist
, vol.14
, pp. 769-779
-
-
Oberic, L.1
-
206
-
-
0029764359
-
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
-
Wang Y et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8568
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 8563-8568
-
-
Wang, Y.1
-
207
-
-
84881389562
-
Targeting the complement system in systemic lupus erythematosus and other diseases
-
Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 2013;148:313-321
-
(2013)
Clin Immunol
, vol.148
, pp. 313-321
-
-
Barilla-Labarca, M.L.1
Toder, K.2
Furie, R.3
-
208
-
-
79957991917
-
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility
-
Zhao J et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011;7:e1002079
-
(2011)
PLoS Genet
, vol.7
, pp. e1002079
-
-
Zhao, J.1
-
209
-
-
84986207697
-
Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus
-
Bermea RS et al. Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus. J Clin Rheumatol 2016;22:320-323
-
(2016)
J Clin Rheumatol
, vol.22
, pp. 320-323
-
-
Bermea, R.S.1
-
210
-
-
84920942686
-
Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy
-
Coppo R et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-172
-
(2015)
Pediatr Nephrol
, vol.30
, pp. 167-172
-
-
Coppo, R.1
-
211
-
-
84922373286
-
Thrombotic microangiopathy in systemic lupus erythematosus: Efficacy of eculizumab
-
El-Husseini A et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015;65:127-130
-
(2015)
Am J Kidney Dis
, vol.65
, pp. 127-130
-
-
El-Husseini, A.1
-
212
-
-
84983094382
-
Eculizumab as rescue therapy in severe resistant lupus nephritis
-
Pickering MC et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 2015;54:2286-2288
-
(2015)
Rheumatology (Oxford)
, vol.54
, pp. 2286-2288
-
-
Pickering, M.C.1
-
213
-
-
85068549807
-
Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab
-
Raufi AG et al. Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab. Hematol Rep 2016;8:6625
-
(2016)
Hematol Rep
, vol.8
, pp. 6625
-
-
Raufi, A.G.1
-
214
-
-
0345328706
-
Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: A case report and literature review
-
Hamasaki K et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol 2003;22:355-358
-
(2003)
Clin Rheumatol
, vol.22
, pp. 355-358
-
-
Hamasaki, K.1
-
215
-
-
70349569565
-
Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies
-
Seshan SV et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 2009;114:1675-1683
-
(2009)
Blood
, vol.114
, pp. 1675-1683
-
-
Seshan, S.V.1
-
216
-
-
0346969977
-
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
-
Girardi G et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654
-
(2003)
J Clin Invest
, vol.112
, pp. 1644-1654
-
-
Girardi, G.1
-
217
-
-
5444270100
-
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice
-
Thurman JM et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005;42:87-97
-
(2005)
Mol Immunol
, vol.42
, pp. 87-97
-
-
Thurman, J.M.1
-
218
-
-
84908664176
-
Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies
-
Romay-Penabad Z et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 2014;23:1324-1326
-
(2014)
Lupus
, vol.23
, pp. 1324-1326
-
-
Romay-Penabad, Z.1
-
219
-
-
84881372189
-
Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes
-
Canaud G et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013;13:2179-2185
-
(2013)
Am J Transplant
, vol.13
, pp. 2179-2185
-
-
Canaud, G.1
-
220
-
-
67449159236
-
Complement activation in patients with primary antiphospholipid syndrome
-
Oku K et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009;68:1030-1035
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1030-1035
-
-
Oku, K.1
-
221
-
-
77954767182
-
Renal involvement in primary antiphospholipid syndrome: Retrospective analysis of 160 patients
-
Sinico RA et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol 2010;5:1211-1217
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 1211-1217
-
-
Sinico, R.A.1
-
222
-
-
84943302788
-
Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis
-
Foltyn Zadura A et al. Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis. J Rheumatol 2015;42:1786-1793
-
(2015)
J Rheumatol
, vol.42
, pp. 1786-1793
-
-
Foltyn Zadura, A.1
-
223
-
-
85016048774
-
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome
-
Barratt-Due A et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology (Oxford) 2016;55:1337-1339
-
(2016)
Rheumatology (Oxford)
, vol.55
, pp. 1337-1339
-
-
Barratt-Due, A.1
-
224
-
-
84917728306
-
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report
-
Kronbichler A et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2014;93:e143
-
(2014)
Medicine (Baltimore)
, vol.93
, pp. e143
-
-
Kronbichler, A.1
-
225
-
-
84864485595
-
Brief report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab
-
Shapira I et al. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012;64:2719-2723
-
(2012)
Arthritis Rheum
, vol.64
, pp. 2719-2723
-
-
Shapira, I.1
-
226
-
-
84961960857
-
A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor
-
Wig S et al. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford) 2016;55:382-384
-
(2016)
Rheumatology (Oxford)
, vol.55
, pp. 382-384
-
-
Wig, S.1
-
227
-
-
84936987706
-
36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: A case report and review of literature
-
Strakhan M et al. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol 2014;2014:704371
-
(2014)
Case Rep Hematol
, vol.2014
, pp. 704371
-
-
Strakhan, M.1
-
228
-
-
84940905884
-
Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome
-
Zikos TA et al. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 2015;21:311-313
-
(2015)
J Clin Rheumatol
, vol.21
, pp. 311-313
-
-
Zikos, T.A.1
-
229
-
-
84857190406
-
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation
-
Hadaya K et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011;11:2523-2527
-
(2011)
Am J Transplant
, vol.11
, pp. 2523-2527
-
-
Hadaya, K.1
-
230
-
-
84905733420
-
A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab
-
Bakhtar O et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation 2014;98:e17-e18
-
(2014)
Transplantation
, vol.98
, pp. e17-e18
-
-
Bakhtar, O.1
-
231
-
-
84895064562
-
Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation
-
Lonze BE etal. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014;14:459-465
-
(2014)
Am J Transplant
, vol.14
, pp. 459-465
-
-
Lonze, B.E.1
-
232
-
-
84995665659
-
Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry
-
Rodriguez-Pinto I et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 2016
-
(2016)
Autoimmun Rev
-
-
Rodriguez-Pinto, I.1
-
233
-
-
84904581191
-
Inhibition of the mTORC pathway in the antiphospholipid syndrome
-
Canaud G et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303-312
-
(2014)
N Engl J Med
, vol.371
, pp. 303-312
-
-
Canaud, G.1
-
234
-
-
62549104828
-
Is complement factor H a susceptibility factor for IgA nephropathy?
-
Edey M et al. Is complement factor H a susceptibility factor for IgA nephropathy? Mol Immunol 2009;46:1405-1408
-
(2009)
Mol Immunol
, vol.46
, pp. 1405-1408
-
-
Edey, M.1
-
235
-
-
0031822961
-
Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy
-
Endo M et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998;13:1984-1990
-
(1998)
Nephrol Dial Transplant
, vol.13
, pp. 1984-1990
-
-
Endo, M.1
-
236
-
-
0031730769
-
Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy
-
Matsuda M et al. Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 1998;80:408-413
-
(1998)
Nephron
, vol.80
, pp. 408-413
-
-
Matsuda, M.1
-
237
-
-
0034751064
-
Mesangial IgA2 deposits and lectin pathwaymediated complement activation in IgA glomerulonephritis
-
Hisano S et al. Mesangial IgA2 deposits and lectin pathwaymediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 2001;38:1082-1088
-
(2001)
Am J Kidney Dis
, vol.38
, pp. 1082-1088
-
-
Hisano, S.1
-
238
-
-
33646924264
-
Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease
-
Roos A et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006;17:1724-1734
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 1724-1734
-
-
Roos, A.1
-
239
-
-
0020120597
-
Partial H (beta 1H) deficiency and glomerulonephritis in two families
-
Wyatt RJ et al. Partial H (beta 1H) deficiency and glomerulonephritis in two families. J Clin Immunol 1982;2:110-117
-
(1982)
J Clin Immunol
, vol.2
, pp. 110-117
-
-
Wyatt, R.J.1
-
240
-
-
79953224410
-
Genome-wide association study identifies susceptibility loci for IgA nephropathy
-
Gharavi AG et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321-327
-
(2011)
Nat Genet
, vol.43
, pp. 321-327
-
-
Gharavi, A.G.1
-
241
-
-
84999762007
-
Rare variants in the complement factor hrelated protein 5 gene contribute to genetic susceptibility to IgA nephropathy
-
Zhai YL et al. Rare variants in the complement factor hrelated protein 5 gene contribute to genetic susceptibility to IgA nephropathy. J Am Soc Nephrol 2016;27:2894-2905
-
(2016)
J Am Soc Nephrol
, vol.27
, pp. 2894-2905
-
-
Zhai, Y.L.1
-
242
-
-
84954067521
-
Use of eculizumab in crescentic IgA nephropathy: Proof of principle and conundrum?
-
Ring T et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015;8:489-491
-
(2015)
Clin Kidney J
, vol.8
, pp. 489-491
-
-
Ring, T.1
-
243
-
-
84930703194
-
Eculizumab treatment for rescue of renal function in IgA nephropathy
-
Rosenblad T et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014;29:2225-2228
-
(2014)
Pediatr Nephrol
, vol.29
, pp. 2225-2228
-
-
Rosenblad, T.1
-
244
-
-
59949101550
-
C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis
-
Schreiber A et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289-298
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 289-298
-
-
Schreiber, A.1
-
245
-
-
33847052568
-
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies
-
Xiao H et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52-64
-
(2007)
Am J Pathol
, vol.170
, pp. 52-64
-
-
Xiao, H.1
-
246
-
-
84893502246
-
C5a receptor (CD88) blockade protects against MPO-ANCA GN
-
Xiao H et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014;25:225-231
-
(2014)
J Am Soc Nephrol
, vol.25
, pp. 225-231
-
-
Xiao, H.1
-
247
-
-
84991696423
-
Antineutrophilic cytoplasmic antibodyassociated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis
-
Fukui S et al. Antineutrophilic cytoplasmic antibodyassociated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine (Baltimore) 2016;95:e4871
-
(2016)
Medicine (Baltimore)
, vol.95
, pp. e4871
-
-
Fukui, S.1
-
248
-
-
84957800791
-
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis
-
Manenti L et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol 2015;10:2143-2151
-
(2015)
Clin J Am Soc Nephrol
, vol.10
, pp. 2143-2151
-
-
Manenti, L.1
-
249
-
-
84978758911
-
Complement in ANCA-associated glomerulonephritis
-
Hilhorst M et al. Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2015
-
(2015)
Nephrol Dial Transplant
-
-
Hilhorst, M.1
-
250
-
-
77954632414
-
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
-
Jones RB et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-220
-
(2010)
N Engl J Med
, vol.363
, pp. 211-220
-
-
Jones, R.B.1
-
251
-
-
84926432207
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
-
Geetha D et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2015;26:976-985
-
(2015)
J Am Soc Nephrol
, vol.26
, pp. 976-985
-
-
Geetha, D.1
-
252
-
-
84886298109
-
The role of complement in membranous nephropathy
-
Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy. Semin Nephrol 2013;33:531-542
-
(2013)
Semin Nephrol
, vol.33
, pp. 531-542
-
-
Ma, H.1
Sandor, D.G.2
Beck, L.H.3
-
253
-
-
4444239340
-
Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy
-
Endo M et al. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract 2004;97:c147-c153
-
(2004)
Nephron Clin Pract
, vol.97
, pp. c147-c153
-
-
Endo, M.1
-
254
-
-
77951253923
-
IgG subclasses and complement pathway in segmental and global membranous nephropathy
-
Segawa Y et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol 2010;25:1091-1099
-
(2010)
Pediatr Nephrol
, vol.25
, pp. 1091-1099
-
-
Segawa, Y.1
-
256
-
-
34249894713
-
A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy
-
Jha V et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18:1899-1904
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1899-1904
-
-
Jha, V.1
-
257
-
-
0023775708
-
Micro-angiopathic haemolysis, thrombocytopenia and nephrotic syndrome associated with membranous nephropathy in a Vietnamese boy
-
McDonald DT, Roy LP. Micro-angiopathic haemolysis, thrombocytopenia and nephrotic syndrome associated with membranous nephropathy in a Vietnamese boy. Aust Paediatr J 1988;24:311-313
-
(1988)
Aust Paediatr J
, vol.24
, pp. 311-313
-
-
McDonald, D.T.1
Roy, L.P.2
-
258
-
-
84884513282
-
Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature
-
Manenti L et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant 2013;28:2246-2259
-
(2013)
Nephrol Dial Transplant
, vol.28
, pp. 2246-2259
-
-
Manenti, L.1
-
259
-
-
11144342822
-
Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases
-
Koulova L et al. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 2005;78:49-54
-
(2005)
Am J Hematol
, vol.78
, pp. 49-54
-
-
Koulova, L.1
-
260
-
-
70249084198
-
Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab
-
Kuppachi S, Chander P, Yoo J. Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab. J Nephrol 2009;22:561-564
-
(2009)
J Nephrol
, vol.22
, pp. 561-564
-
-
Kuppachi, S.1
Chander, P.2
Yoo, J.3
-
261
-
-
84947460124
-
Complement activation in patients with focal segmental glomerulosclerosis
-
Thurman JM et al. Complement activation in patients with focal segmental glomerulosclerosis. PLoS One 2015;10:e0136558
-
(2015)
PLoS One
, vol.10
, pp. e0136558
-
-
Thurman, J.M.1
-
262
-
-
85021137566
-
Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis
-
Zhang YM et al. Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2016;11:1582-1589
-
(2016)
Clin J Am Soc Nephrol
, vol.11
, pp. 1582-1589
-
-
Zhang, Y.M.1
-
263
-
-
85038031095
-
Thrombotic microangiopathy in inverted formin 2-mediated renal disease
-
Challis RC et al. Thrombotic microangiopathy in inverted formin 2-mediated renal disease. J Am Soc Nephrol 2016
-
(2016)
J Am Soc Nephrol
-
-
Challis, R.C.1
-
264
-
-
59149100961
-
Renal biopsy findings predicting outcome in scleroderma renal crisis
-
Batal I et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009;40:332-340
-
(2009)
Hum Pathol
, vol.40
, pp. 332-340
-
-
Batal, I.1
-
265
-
-
84922695299
-
The local complement activation on vascular bed of patients with systemic sclerosis: A hypothesisgenerating study
-
Scambi C et al. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesisgenerating study. PLoS One 2015;10:e0114856
-
(2015)
PLoS One
, vol.10
, pp. e0114856
-
-
Scambi, C.1
-
266
-
-
84982804500
-
Complement activation and effect of eculizumab in scleroderma renal crisis
-
Devresse A et al. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore) 2016;95:e4459
-
(2016)
Medicine (Baltimore)
, vol.95
, pp. e4459
-
-
Devresse, A.1
-
267
-
-
84959365593
-
Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome
-
Thomas CP et al. Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome. Clin Kidney J 2015;8:698-701
-
(2015)
Clin Kidney J
, vol.8
, pp. 698-701
-
-
Thomas, C.P.1
-
268
-
-
84988372364
-
Scleroderma renal crisis and renal involvement in systemic sclerosis
-
Woodworth TG et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 2016
-
(2016)
Nat Rev Nephrol
-
-
Woodworth, T.G.1
-
269
-
-
84871212143
-
Prognosis of scleroderma renal crisis: A longterm observational study
-
Cozzi F et al. Prognosis of scleroderma renal crisis: a longterm observational study. Nephrol Dial Transplant 2012;27:4398-4403
-
(2012)
Nephrol Dial Transplant
, vol.27
, pp. 4398-4403
-
-
Cozzi, F.1
-
270
-
-
33745441327
-
Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice
-
Pickering MC et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 2006;103:9649-9654
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 9649-9654
-
-
Pickering, M.C.1
-
271
-
-
84864554927
-
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies
-
Servais A et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-464
-
(2012)
Kidney Int
, vol.82
, pp. 454-464
-
-
Servais, A.1
-
272
-
-
84958237174
-
Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome
-
Iatropoulos P et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 2016;71:131-142
-
(2016)
Mol Immunol
, vol.71
, pp. 131-142
-
-
Iatropoulos, P.1
-
273
-
-
84860779074
-
Eculizumab for dense deposit disease and C3 glomerulonephritis
-
Bomback AS et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012;7:748-756
-
(2012)
Clin J Am Soc Nephrol
, vol.7
, pp. 748-756
-
-
Bomback, A.S.1
-
274
-
-
84858633062
-
Eculizumab and refractory membranoproliferative glomerulonephritis
-
Radhakrishnan S et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012;366:1165-1166
-
(2012)
N Engl J Med
, vol.366
, pp. 1165-1166
-
-
Radhakrishnan, S.1
-
275
-
-
84863881370
-
Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis
-
Brackman D et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant 2011;26:3399-3403
-
(2011)
Nephrol Dial Transplant
, vol.26
, pp. 3399-3403
-
-
Brackman, D.1
-
276
-
-
84883261341
-
Eculizumab and recurrent C3 glomerulonephritis
-
Gurkan S et al. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 2013;28:1975-1981
-
(2013)
Pediatr Nephrol
, vol.28
, pp. 1975-1981
-
-
Gurkan, S.1
-
277
-
-
84990841054
-
Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy
-
Kersnik Levart T et al. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Diagn Pathol 2016;11:94
-
(2016)
Diagn Pathol
, vol.11
, pp. 94
-
-
Kersnik Levart, T.1
-
278
-
-
84959490254
-
Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease
-
Tran CL et al. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol 2016;31:683-687
-
(2016)
Pediatr Nephrol
, vol.31
, pp. 683-687
-
-
Tran, C.L.1
-
279
-
-
84858661698
-
Eculizumab for the treatment of dense-deposit disease
-
Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012;366:1163-1165
-
(2012)
N Engl J Med
, vol.366
, pp. 1163-1165
-
-
Vivarelli, M.1
Pasini, A.2
Emma, F.3
-
280
-
-
84901641827
-
Rituximab fails where eculizumab restores renal function in C3nef-related DDD
-
Rousset-Rouviere C et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014;29:1107-1111
-
(2014)
Pediatr Nephrol
, vol.29
, pp. 1107-1111
-
-
Rousset-Rouviere, C.1
-
281
-
-
84939939865
-
A case of C3 glomerulonephritis successfully treated with eculizumab
-
Payette A et al. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 2015;30:1033-1037
-
(2015)
Pediatr Nephrol
, vol.30
, pp. 1033-1037
-
-
Payette, A.1
-
282
-
-
84858671433
-
Eculizumab in a patient with dense-deposit disease
-
Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012;366:1161-1163
-
(2012)
N Engl J Med
, vol.366
, pp. 1161-1163
-
-
Daina, E.1
Noris, M.2
Remuzzi, G.3
-
283
-
-
84942087191
-
Eculizumab-induced reversal of dialysisdependent kidney failure from C3 glomerulonephritis
-
Inman M et al. Eculizumab-induced reversal of dialysisdependent kidney failure from C3 glomerulonephritis. Clin Kidney J 2015;8:445-448
-
(2015)
Clin Kidney J
, vol.8
, pp. 445-448
-
-
Inman, M.1
-
284
-
-
84924119716
-
Eculizumab for treatment of rapidly progressive C3 glomerulopathy
-
Le Quintrec M et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 2015;65:484-489
-
(2015)
Am J Kidney Dis
, vol.65
, pp. 484-489
-
-
Le Quintrec, M.1
-
285
-
-
84943795891
-
Eculizumab in pediatric dense deposit disease
-
Oosterveld MJ et al. Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol 2015;10:1773-1782
-
(2015)
Clin J Am Soc Nephrol
, vol.10
, pp. 1773-1782
-
-
Oosterveld, M.J.1
-
286
-
-
84901672159
-
Eculizumab therapy in a patient with densedeposit disease associated with partial lipodystropy
-
Ozkaya O et al. Eculizumab therapy in a patient with densedeposit disease associated with partial lipodystropy. Pediatr Nephrol 2014;29:1283-1287
-
(2014)
Pediatr Nephrol
, vol.29
, pp. 1283-1287
-
-
Ozkaya, O.1
-
287
-
-
84859421387
-
Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies
-
McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012;12:1046-1051
-
(2012)
Am J Transplant
, vol.12
, pp. 1046-1051
-
-
McCaughan, J.A.1
O'Rourke, D.M.2
Courtney, A.E.3
-
288
-
-
84930251736
-
Eculizumab in dense-deposit disease after renal transplantation
-
Sanchez-Moreno A et al. Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 2014;29:2055-2059
-
(2014)
Pediatr Nephrol
, vol.29
, pp. 2055-2059
-
-
Sanchez-Moreno, A.1
-
289
-
-
84979198208
-
Complement, thrombotic microangiopathy and disseminated intravascular coagulation
-
Kurosawa S, Stearns-Kurosawa DJ. Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care 2014;2:65
-
(2014)
J Intensive Care
, vol.2
, pp. 65
-
-
Kurosawa, S.1
Stearns-Kurosawa, D.J.2
-
290
-
-
84947260202
-
An international consensus approach to the management of atypical hemolytic uremic syndrome in children
-
Loirat C et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016;31:15-39
-
(2016)
Pediatr Nephrol
, vol.31
, pp. 15-39
-
-
Loirat, C.1
-
291
-
-
84964533992
-
Eculizumab in children with hemolytic uremic syndrome
-
Kavanagh D, Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int 2016;89:537-538
-
(2016)
Kidney Int
, vol.89
, pp. 537-538
-
-
Kavanagh, D.1
Smith-Jackson, K.2
-
292
-
-
84973267298
-
Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)
-
Wong E et al. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016;221:715-718
-
(2016)
Immunobiology
, vol.221
, pp. 715-718
-
-
Wong, E.1
-
293
-
-
77957602545
-
Transplantation in atypical hemolytic uremic syndrome
-
Kavanagh D et al. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:653-659
-
(2010)
Semin Thromb Hemost
, vol.36
, pp. 653-659
-
-
Kavanagh, D.1
-
294
-
-
0142250921
-
Thrombotic microangiopathy after renal transplantation in the United States
-
Reynolds JC et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003;42:1058-1068
-
(2003)
Am J Kidney Dis
, vol.42
, pp. 1058-1068
-
-
Reynolds, J.C.1
-
295
-
-
33748512369
-
Thrombotic microangiopathy after kidney transplantation
-
Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation. Transpl Int 2006;19:789-794
-
(2006)
Transpl Int
, vol.19
, pp. 789-794
-
-
Ponticelli, C.1
Banfi, G.2
-
296
-
-
84884821706
-
Targeted strategies in the prevention and managementof atypical HUS recurrence after kidney transplantation
-
Zuber J et al. Targeted strategies in the prevention and managementof atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 2013;27:117-125
-
(2013)
Transplant Rev (Orlando)
, vol.27
, pp. 117-125
-
-
Zuber, J.1
-
297
-
-
84923996371
-
De novo thrombotic microangiopathy after non-renal solid organ transplantation
-
Verbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev 2014;28:269-279
-
(2014)
Blood Rev
, vol.28
, pp. 269-279
-
-
Verbiest, A.1
Pirenne, J.2
Dierickx, D.3
-
298
-
-
77954901670
-
De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection
-
Satoskar AA et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010;10:1804-1811
-
(2010)
Am J Transplant
, vol.10
, pp. 1804-1811
-
-
Satoskar, A.A.1
-
299
-
-
84959440372
-
The Revised (2013) Banff Classification for antibody-mediated rejection of renal allografts: Update, difficulties, and future considerations
-
Haas M. The Revised (2013) Banff Classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transplant 2016;16:1352-1357
-
(2016)
Am J Transplant
, vol.16
, pp. 1352-1357
-
-
Haas, M.1
-
300
-
-
84874633763
-
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN
-
Ozaltin F et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013;24:377-384
-
(2013)
J Am Soc Nephrol
, vol.24
, pp. 377-384
-
-
Ozaltin, F.1
-
301
-
-
84867997580
-
STEC-HUS, atypical HUS and TTP are all diseases of complement activation
-
Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-633
-
(2012)
Nat Rev Nephrol
, vol.8
, pp. 622-633
-
-
Noris, M.1
Mescia, F.2
Remuzzi, G.3
-
303
-
-
84964765602
-
Pregnancy-related thrombotic microangiopathies: Clues from complement biology
-
Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci 2016;54:199-202
-
(2016)
Transfus Apher Sci
, vol.54
, pp. 199-202
-
-
Fakhouri, F.1
-
304
-
-
0042703238
-
The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
-
George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003;10:339-344
-
(2003)
Curr Opin Hematol
, vol.10
, pp. 339-344
-
-
George, J.N.1
-
305
-
-
84876823275
-
Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy
-
Fakhouri F, Vercel C, Fremeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 2012;7:2100-2106
-
(2012)
Clin J Am Soc Nephrol
, vol.7
, pp. 2100-2106
-
-
Fakhouri, F.1
Vercel, C.2
Fremeaux-Bacchi, V.3
-
306
-
-
77956061313
-
Pre-eclampsia
-
Steegers EA et al. Pre-eclampsia. Lancet 2010;376:631-644
-
(2010)
Lancet
, vol.376
, pp. 631-644
-
-
Steegers, E.A.1
-
307
-
-
0036707878
-
Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: Upregulation of globotriaosylceramide expression
-
Hughes AK et al. Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression. J Am Soc Nephrol 2002;13:2239-2245
-
(2002)
J Am Soc Nephrol
, vol.13
, pp. 2239-2245
-
-
Hughes, A.K.1
-
308
-
-
79952087639
-
Escherichia coli Shiga toxin mechanisms of action in renal disease
-
Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010;2:2769-2794
-
(2010)
Toxins (Basel)
, vol.2
, pp. 2769-2794
-
-
Obrig, T.G.1
-
309
-
-
68549099868
-
Pathogenesis of thrombotic microangiopathy: Insights from animal models
-
Richards A, Kavanagh D. Pathogenesis of thrombotic microangiopathy: insights from animal models. Nephron Exp Nephrol 2009;113:e97-e103
-
(2009)
Nephron Exp Nephrol
, vol.113
, pp. e97-e103
-
-
Richards, A.1
Kavanagh, D.2
-
310
-
-
84941369290
-
Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement
-
Pape L et al. Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 2015;94:e1000
-
(2015)
Medicine (Baltimore)
, vol.94
, pp. e1000
-
-
Pape, L.1
-
311
-
-
84867993202
-
Renal and neurological involvement in typical Shiga toxin-associated HUS
-
Trachtman H et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012;8:658-669
-
(2012)
Nat Rev Nephrol
, vol.8
, pp. 658-669
-
-
Trachtman, H.1
-
312
-
-
80051916351
-
Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America
-
Banerjee R et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect DisJ 2011;30:736-739
-
(2011)
Pediatr Infect DisJ
, vol.30
, pp. 736-739
-
-
Banerjee, R.1
-
313
-
-
84855182718
-
Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan
-
Lee CS et al. Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan. Nephrology (Carlton) 2012;17:48-52
-
(2012)
Nephrology (Carlton)
, vol.17
, pp. 48-52
-
-
Lee, C.S.1
-
314
-
-
73449116405
-
Ten years of pneumococcalassociated haemolytic uraemic syndrome in New Zealand children
-
Prestidge C, Wong W. Ten years of pneumococcalassociated haemolytic uraemic syndrome in New Zealand children. J Paediatr Child Health 2009;45:731-735
-
(2009)
J Paediatr Child Health
, vol.45
, pp. 731-735
-
-
Prestidge, C.1
Wong, W.2
-
315
-
-
34447539658
-
Hemolytic uremic syndrome associated with invasive pneumococcal disease: The United Kingdom experience
-
Waters AM et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151:140-144
-
(2007)
J Pediatr
, vol.151
, pp. 140-144
-
-
Waters, A.M.1
-
316
-
-
84924894624
-
Structural basis for sialic acid-mediated self-recognition by complement factor H
-
Blaum BS et al. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol 2015;11:77-82
-
(2015)
Nat Chem Biol
, vol.11
, pp. 77-82
-
-
Blaum, B.S.1
-
317
-
-
79961011284
-
Viral-associated thrombotic microangiopathies
-
Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther 2011;4:51-59
-
(2011)
Hematol Oncol Stem Cell Ther
, vol.4
, pp. 51-59
-
-
Lopes Da Silva, R.1
-
318
-
-
0036151680
-
Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virusinfected macaques
-
Segerer S et al. Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virusinfected macaques. J Am Soc Nephrol 2002;13:370-378
-
(2002)
J Am Soc Nephrol
, vol.13
, pp. 370-378
-
-
Segerer, S.1
-
319
-
-
85038028809
-
Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplantassociated thrombotic microangiopathy?
-
Dhakal P, Bhatt VR. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplantassociated thrombotic microangiopathy? Bone Marrow Transplant 2016
-
(2016)
Bone Marrow Transplant
-
-
Dhakal, P.1
Bhatt, V.R.2
-
320
-
-
13144265709
-
Microangiopathic hemolysis and renal failure in malignant hypertension
-
van den Born BJ et al. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005;45:246-251
-
(2005)
Hypertension
, vol.45
, pp. 246-251
-
-
Van Den Born, B.J.1
-
321
-
-
34547418087
-
The renin-angiotensin system in malignant hypertension revisited: Plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension
-
van den Born BJ, Koopmans RP, van Montfrans GA. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens 2007;20:900-906
-
(2007)
Am J Hypertens
, vol.20
, pp. 900-906
-
-
Van Den Born, B.J.1
Koopmans, R.P.2
Van Montfrans, G.A.3
-
322
-
-
84864371299
-
Long-term renal outcome in patients with malignant hypertension: A retrospective cohort study
-
Amraoui F et al. Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study. BMC Nephrol 2012;13:71
-
(2012)
BMC Nephrol
, vol.13
, pp. 71
-
-
Amraoui, F.1
-
323
-
-
85019135806
-
Severe hypertension with renal thrombotic microangiopathy: What happened to the usual suspect?
-
Van Laecke S, Van Biesen W. Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? Kidney Int 2017;91:1271-1274
-
(2017)
Kidney Int
, vol.91
, pp. 1271-1274
-
-
Van Laecke, S.1
Van Biesen, W.2
-
324
-
-
85011579203
-
Patients with hypertensionassociated thrombotic microangiopathy may present with complement abnormalities
-
Timmermans S et al. Patients with hypertensionassociated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-1425
-
(2017)
Kidney Int
, vol.91
, pp. 1420-1425
-
-
Timmermans, S.1
-
325
-
-
76649090941
-
Severe renal failure and microangiopathic hemolysis induced by malignant hypertension-case series and review of literature
-
Shavit L, Reinus C, Slotki I. Severe renal failure and microangiopathic hemolysis induced by malignant hypertension-case series and review of literature. Clin Nephrol 2010;73:147-152
-
(2010)
Clin Nephrol
, vol.73
, pp. 147-152
-
-
Shavit, L.1
Reinus, C.2
Slotki, I.3
-
326
-
-
84921646968
-
Drug-induced thrombotic microangiopathy: A systematic review of published reports
-
Al-Nouri ZL et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015;125:616-618
-
(2015)
Blood
, vol.125
, pp. 616-618
-
-
Al-Nouri, Z.L.1
-
327
-
-
84999881304
-
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
-
Kavanagh D et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016
-
(2016)
Blood
-
-
Kavanagh, D.1
-
328
-
-
84896996710
-
Thrombotic microangiopathy associated with interferon beta
-
Hunt D et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med 2014;370:1270-1271
-
(2014)
N Engl J Med
, vol.370
, pp. 1270-1271
-
-
Hunt, D.1
-
329
-
-
40849130173
-
VEGF inhibition and renal thrombotic microangiopathy
-
Eremina V et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136
-
(2008)
N Engl J Med
, vol.358
, pp. 1129-1136
-
-
Eremina, V.1
-
330
-
-
84945437213
-
Thrombotic microangiopathy, cancer, and cancer drugs
-
Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015;66:857-868
-
(2015)
Am J Kidney Dis
, vol.66
, pp. 857-868
-
-
Izzedine, H.1
Perazella, M.A.2
-
331
-
-
0018675341
-
Microangiopathic hemolytic anemia and cancer: A review
-
Antman KH et al. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979;58:377-384
-
(1979)
Medicine (Baltimore)
, vol.58
, pp. 377-384
-
-
Antman, K.H.1
-
332
-
-
80053633983
-
Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia
-
George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) 2011;25:908-914
-
(2011)
Oncology (Williston Park)
, vol.25
, pp. 908-914
-
-
George, J.N.1
-
333
-
-
77953717551
-
Complement factor H autoantibodies are associated with early stage NSCLC
-
Amornsiripanitch N et al. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 2010;16:3226-3231
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3226-3231
-
-
Amornsiripanitch, N.1
-
334
-
-
36049001153
-
Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis
-
Benz K et al. Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis. Pediatr Nephrol 2007;22:2125-2128
-
(2007)
Pediatr Nephrol
, vol.22
, pp. 2125-2128
-
-
Benz, K.1
-
335
-
-
0026649518
-
Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis
-
Bokenkamp A et al. Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis. Eur J Pediatr 1992;151:791-792
-
(1992)
Eur J Pediatr
, vol.151
, pp. 791-792
-
-
Bokenkamp, A.1
-
336
-
-
84925620174
-
Podocyte dysfunction in atypical haemolytic uraemic syndrome
-
Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2015;11:245-252
-
(2015)
Nat Rev Nephrol
, vol.11
, pp. 245-252
-
-
Noris, M.1
Mele, C.2
Remuzzi, G.3
-
337
-
-
0029826567
-
Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome
-
Caletti MG, Gallo G, Gianantonio CA. Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome. Pediatr Nephrol 1996;10:687-692
-
(1996)
Pediatr Nephrol
, vol.10
, pp. 687-692
-
-
Caletti, M.G.1
Gallo, G.2
Gianantonio, C.A.3
-
338
-
-
33845387138
-
A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy
-
Chang A et al. A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. Clin Nephrol 2006;66:397-404
-
(2006)
Clin Nephrol
, vol.66
, pp. 397-404
-
-
Chang, A.1
-
339
-
-
84855583592
-
A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy
-
El Karoui K et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012;23:137-148
-
(2012)
J Am Soc Nephrol
, vol.23
, pp. 137-148
-
-
El Karoui, K.1
-
340
-
-
84980332096
-
Insights into kidney diseases from genome-wide association studies
-
Wuttke M, Kottgen A. Insights into kidney diseases from genome-wide association studies. Nat Rev Nephrol 2016;12:549-562
-
(2016)
Nat Rev Nephrol
, vol.12
, pp. 549-562
-
-
Wuttke, M.1
Kottgen, A.2
-
341
-
-
84929169595
-
Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis
-
Chen SF et al. Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin J Am Soc Nephrol 2015;10:750-758
-
(2015)
Clin J Am Soc Nephrol
, vol.10
, pp. 750-758
-
-
Chen, S.F.1
-
342
-
-
0018137313
-
Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis
-
Dische FE, Culliford EJ, Parsons V. Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis. Br Med J 1978;1:1112-1113
-
(1978)
Br Med J
, vol.1
, pp. 1112-1113
-
-
Dische, F.E.1
Culliford, E.J.2
Parsons, V.3
-
343
-
-
0025972826
-
Recurrent thrombotic thrombocytopenic purpura associated with membranous glomerulopathy
-
Friedlander MA, Jacobs GH. Recurrent thrombotic thrombocytopenic purpura associated with membranous glomerulopathy. Am J Kidney Dis 1991;17:83-85
-
(1991)
Am J Kidney Dis
, vol.17
, pp. 83-85
-
-
Friedlander, M.A.1
Jacobs, G.H.2
-
344
-
-
84921437508
-
Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN
-
Wong EK et al. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol 2014;25:2425-2433
-
(2014)
J Am Soc Nephrol
, vol.25
, pp. 2425-2433
-
-
Wong, E.K.1
-
345
-
-
84863511490
-
A hybrid CFHR3-1 gene causes familial C3 glomerulopathy
-
Malik TH et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012;23:1155-1160
-
(2012)
J Am Soc Nephrol
, vol.23
, pp. 1155-1160
-
-
Malik, T.H.1
-
346
-
-
33745697887
-
Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)
-
Licht C et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006;70:42-50
-
(2006)
Kidney Int
, vol.70
, pp. 42-50
-
-
Licht, C.1
-
347
-
-
84862301748
-
Factor H autoantibodies in membranoproliferative glomerulonephritis
-
Goodship TH et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 2012;52:200-206
-
(2012)
Mol Immunol
, vol.52
, pp. 200-206
-
-
Goodship, T.H.1
-
348
-
-
77956394517
-
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis
-
Gale DP et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010;376:794-801
-
(2010)
Lancet
, vol.376
, pp. 794-801
-
-
Gale, D.P.1
-
349
-
-
40849147541
-
Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits
-
Boyer O et al. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis 2008;51:671-677
-
(2008)
Am J Kidney Dis
, vol.51
, pp. 671-677
-
-
Boyer, O.1
-
350
-
-
80155136247
-
Three kidneys, two diseases, one antibody?
-
Lorcy N et al. Three kidneys, two diseases, one antibody? Nephrol Dial Transplant 2011;26:3811-3813
-
(2011)
Nephrol Dial Transplant
, vol.26
, pp. 3811-3813
-
-
Lorcy, N.1
-
351
-
-
0346656641
-
Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome
-
Cooper M et al. Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome. Nephrol Dial Transplant 2004;19:230-233
-
(2004)
Nephrol Dial Transplant
, vol.19
, pp. 230-233
-
-
Cooper, M.1
-
352
-
-
84982915216
-
Renal thrombotic microangiopathy in proliferative lupus nephritis: Risk factors and clinical outcomes: A case-control study
-
Barrera-Vargas A et al. Renal thrombotic microangiopathy in proliferative lupus nephritis: risk factors and clinical outcomes: a case-control study. J Clin Rheumatol 2016;22:235-240
-
(2016)
J Clin Rheumatol
, vol.22
, pp. 235-240
-
-
Barrera-Vargas, A.1
-
353
-
-
84860763334
-
Evaluation of clinical outcomes and renal vascular pathology among patients with lupus
-
Barber C et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 2012;7:757-764
-
(2012)
Clin J Am Soc Nephrol
, vol.7
, pp. 757-764
-
-
Barber, C.1
-
354
-
-
84939541475
-
Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome
-
Hernandez-Molina G et al. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol 2015;33:503-508
-
(2015)
Clin Exp Rheumatol
, vol.33
, pp. 503-508
-
-
Hernandez-Molina, G.1
-
355
-
-
84952013335
-
Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis
-
Ghossein C, Varga J, Fenves AZ. Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis. Curr Rheumatol Rep 2016;18:5
-
(2016)
Curr Rheumatol Rep
, vol.18
, pp. 5
-
-
Ghossein, C.1
Varga, J.2
Fenves, A.Z.3
-
356
-
-
85038010060
-
Highly specialised technologies: Eculizumab for treating atypical haemolytic uraemic syndrome
-
National Institute for Health and Care Excellence
-
National Institute for Health and Care Excellence. Highly specialised technologies: Eculizumab for treating atypical haemolytic uraemic syndrome. NICE 2015, p. 7
-
(2015)
NICE
, pp. 7
-
-
|